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Bronchiolitis obliterans syndrome (BOS) represents the leading cause of late mortality after
lung transplantation (LTx). Cystic fibrosis (CF) patients frequently show airway colonization
with gram-negative bacteria (GNB) both before and after LTx. Graft colonization with GNB
and its relevance towards BOS development were investigated in a CF population after LTx.
Adult CF patients receiving LTx and surviving at least 6 months were included in this prospec-
tive observational study between 1/1/2002 and 30/6/2006 in a single center and followed until
31/3/2007. Pre- and post-LTx respiratory culture samples were compared for the presence of
identical GNB. BOS-free survival was compared in colonized and non-colonized patients.
Fifty-nine adult CF patients with a median age at LTx of 25.5 (18e49) years were included
and had a median follow-up of 966 (128e1889) days. Seven patients (15%) demonstrated imme-
diate eradication of GNB in lower respiratory tract samples. A further 18 patients (34%) demon-
strated transient colonization. Thirty-four recipients had further positive samples after LTx.
Eighteen patients (31%) developed BOS stage 1, 508 (114e1167) days after LTx. Freedom
of graft colonization with pseudomonads was independently associated with less frequent
development of BOS (pZ 0.006).15323560; fax: þ49 5115323353.
hannover.de (J. Gottlieb).
8 Elsevier Ltd. All rights reserved.
744 J. Gottlieb et al.Persistent graft colonization with pseudomonads increases the prevalence of BOS after LTx
in CF patients. A significant proportion of post-LTx CF patients demonstrates subsequent GNB
eradication during later follow-up and this may have a protective role against development of
BOS. Strategies to eradicate airway colonization or reduce bacterial load may prevent BOS in
CF patients after LTx.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
Lung transplantation is an accepted therapeutic option for
patients with a variety of end-stage pulmonary disorders.
Quality of life and short-term survival are improved with
transplantation, but long-term survival is limited by the
development of chronic organ dysfunction as the leading
cause of late mortality.1 Bronchiolitis obliterans syndrome
(BOS) is the clinical definition of chronic organ dysfunction
and refers to a progressive obstructive ventilatory
disorder.2 BOS affects approximately one-third of lung
transplant recipients 3 years after lung transplantation,
and half of all recipients after 5 years.1 It remains the
leading cause of death after first post-operative year.1
Infections are potential risk factors for the development of
BOS.3
Lower airway tract colonization is a common phenom-
enon in patients with impaired pulmonary defences and
airway remodeling, as in chronic obstructive pulmonary
disease (COPD), bronchiectasis and cystic fibrosis (CF).4e6
Pseudomonas aeruginosa (PSA) and other non-fermenting
bacteria are the dominant pathogens in CF patients pre-
senting for lung transplantation.5 Four separate categories
(free, never, intermittent or chronic) of chronic P. aerugi-
nosa infection in children with cystic fibrosis (CF) have been
previously defined, based on airway cultures taken over the
previous year.7 Pseudomonad colonization remains detect-
able intermittently after lung transplantation in most
recipients with CF after lung transplantation.8,9
The aim of this study was to assess the impact of airway
re-colonization with gram-negative bacteria in CF patients
after LTx and to investigate the association to the devel-
opment of BOS.Methods
Transplant population
This cohort study was performed in a single university
hospital with a high-volume lung transplant program and
a large adult cystic fibrosis service. The recruitment period
lasted from 1st January 2002 until 30th June 2006.
Throughout this period, all adult cystic fibrosis patients
(>18 years) who exhibited at least one confirmed isolate
of GNB in the year prior to transplant were included in
the study. GNB was defined as isolation of at least one
pseudomonad (P. aeruginosa, Burkholderia cepacia, Ach-
romobacter or Stenotrophomonas). All patients exhibiting
a post-operative survival of less than 6 months or
undergoing re-do-transplantation were excluded. Addi-
tional exclusion criteria loss of follow-up and patientswith less than five suitable post-operative culture
samples.
All lung transplant recipients received frequent indi-
vidual center-based follow-up care scheduled
throughout the post-operative period with a maximum
interval between assessments of 3 months. Follow-up
data were recorded until 31st March 2007. At each
follow-up visit, patients received comprehensive clinical
examination. Quantitative assessment consisted of
spirometry in conjunction with blood gas analysis,
measurement of immunosuppressive drug levels and
chest radiographs.
Spirometry was performed according to ATS/ERS guide-
lines.10 BOS staging was defined as a FEV1 <80% best after
transplantation according to the International Society of
Heart and Lung Transplantation (ISHLT) system.11 Baseline
FEV1 was defined as the average of the two highest
measurements obtained at least 3 weeks apart during the
post-operative course.
Immunosuppression
Standard maintenance immunosuppression consisted of
a triple drug regimen including a calcineurin inhibitor,
prednisolone, and a cell-cycle inhibitor or an mTOR
(mammalian target of rapamycin)-inhibitor. Calcineurin
inhibitor (CNI)-free protocols were not applied. Target
trough levels of CNIs were gradually reduced to ciclosporin
levels of 100e150 ng/ml after the second post-operative
year and target trough levels for tacrolimus (EMIT, Behring,
Germany) of 8e12 ng/ml. Prednisolone was tapered in all
recipients during the first 3 post-operative months to a dose
of 0.07e0.1 mg/kg afterwards. Long-term azithromycin
(250 mg orally three times/week) was the standard of care
for patients with BOS in this study while augmentation of
immunosuppression was avoided.
No routine induction therapy was used. Between
January 2003 and May 2005 eight patients were treated
with daclizumab in a randomized controlled trial
compared to placebo. The perioperative antibiotic
regimen in CF patients undergoing lung transplantation in
our program consisted of a post-operative intravenous
combination regimen (according to preoperative suscep-
tibility testing) for 2 weeks. Nebulized colomycin (two
mega units, b.i.d for 3 months) was used for patients
colonized with Pseudomonas pre-transplant. Sinus surgery
was performed before transplantation or thereafter if
clinically indicated.
Acute rejection (AR) therapy was defined as any steroid
pulse (15 mg/kg methylprednisolone on 3 consecutive
days). Episodes of AR during the first 4 post-operative
weeks were excluded.
Table 1 Patient demographics (nZ 59).
Age, years 25.5 (18e49)
Gender, female 31 (53%)
Follow-up, days 963 447
Best FEV1, % predicted 76 21
Double lung transplantation 59 (100%)
Liverelung transplantation 3 (5%)
Operation time, min 276 58
Cardiopulmonary bypass use 21 (36%)
Minimal invasive surgery 44 (75%)
ICU length of stay< 96 h 43 (73%)
Pre-transplant mechanical ventilation 6 (10%)
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Pre-transplant respiratory samples were sputum cultures,
no bronchoscopy was performed before transplantation.
Bronchoscopy with BAL was performed on post-operative
day 0, 5 1, 21 2 and 100 7 on all patients included in
the study. Further bronchoscopy with bronchoalveolar
lavage (BAL) and transbronchial biopsy was performed
based on clinical decision at any time during transplant
follow-up. Regular surveillance bronchoscopies were not
part of our clinical program in patients beyond the first 3
post-operative months. Samples were taken from patients
using a flexible fiberoptic bronchoscope introduced via the
nasal route after cleaning the nostrils. Anaesthetics were
instilled via a special catheter introduced through the
working channel of the bronchoscope and removed after
instillation.
BAL was performed according to standard recommen-
dations.12 The bronchoscope was wedged into a sub-
segmental bronchus of either the lingula or the right middle
lobe. BAL was performed by instilling a total of 120 ml of
isotonic saline solution, warmed to 37 C in sequential 20-
ml aliquots. The first 20-ml-aliquot was discarded and was
not used for quantitative cultures. The fluid fractions were
aspirated with gentle low-pressure suction into a sterilised
silicon container. The fluid retrieved was pooled and the
total recovered volume was measured. Samples of fluid
were processed immediately for cytological, viral and
microbiological analyses.
Other methods of lower respiratory tract sampling
(sputum samples, aspirates or bronchial washing) were
performed only if BAL was not tolerated or feasible.
Preoperative isolates were retrieved from sputum
samples and post-operative isolates from bronchoalveolar
lavage (BAL), aspirates and/or bronchial washing. Quanti-
tative cultures with counts of colony forming units per ml in
BAL fluid (BALF) were performed routinely throughout the
study period. All material sent to the laboratory was
cultured according to routine diagnostic procedures. Serial
dilutions from each BAL sample were prepared in sterile
normal saline. For BAL culture, BALF was serially diluted
onto different media depending on clinical suspicion. The
presence of one or more bacterial colonies after 48 h of
incubation was considered significant. Quantitative
cultures were expressed as colony forming units (isolated,
102, 103, 104, 105/ml). Based on the results in previous
studies, BALF was considered to be not or marginally
contaminated, if the specimen contained <102 CFU
patients of oropharyngeal flora, no ciliated epithelial cells,
and <1% squamous epithelial cells.
All microorganisms isolated were identified by standard
laboratory methods. The presence or absence of a mucoid
phenotype on Pseudomonas isolation agar plates was
recorded for each isolate. Antibiograms of all pseudomo-
nads pre- and post-transplantation were compared for
every isolate to identify identical GNB. Occasionally pulsed-
field gel-electrophoresis was used as described previously
to genotype GNB in cases demonstrating equivocal
results.9,13 Identical GNBecolonization of the graft was
defined by any growth of the same pre-transplant gram-
negative bacterial pathogen in a respiratory sample.Colonization of the graft was defined by repeated detection
on at least two occasions by pulmonary pathogens regard-
less of the presence of signs of infection. No cut-off value
for quantitative BAL cultures was used. Loss of colonization
was defined of three or more consecutive GNB-negative
materials more than 14 days apart.
Ethics
Approval from the local Ethics Committee was obtained to
conduct the investigation. Patients gave informed consent
prior to inclusion into the study.
Statistical analysis
Data are reported as means (standard deviation), time
dependent variables are expressed as median (minimum
and maximum). All reported p-values are two-sided, unless
otherwise indicated. For all analyses, p-values <0.05 were
considered statistically significant.
Univariate analysis: Categorical variables were analyzed
by the Chi-squared test or Fisher’s exact test. Medians were
analyzed with the ManneWhitney test. Means were
analyzed with Student’s t-test. Univariate analysis of risk
factors for BOS was performed using the log rank test.
Multivariate analysis included Cox stepwise forward
regression analysis (for endpoint BOS-free survival). All
variables with a p-value 0.10 were included and variables
with a p-value of >0.10 were excluded in multivariate
analysis.
Results
Patient characteristics are shown in Table 1. Group A
(nZ 25) consisted of seven of the 59 recipients remaining
GNB-free from the outset along with 18 patients who were
transiently colonized with identical GNB but subsequently
cleared GNB in the following 224 (77e1173) days after LTx.
Group B were those patients in whom intermittent or
chronic GNB in respiratory samples were cultured (nZ 34)
(Fig. 1). No patient became GNB-negative after developing
BOS during follow-up. Nine patients (group A, nZ 5; group
B, nZ 4) demonstrated transient de-novo colonization with
a second gram-negative pathogens after LTx.
One thousand four hundred and thirty-two respiratory
samples in total and 532 BALF (37%) were collected after
Figure 1 Flow-chart of study design.
Table 2 Univariate analysis comparing CF-patients losing
746 J. Gottlieb et al.transplantation in 59 patients, averaging 24 samples (range
6e56) and 9 5 BALF/patient. The majority of all samples
(52%) contained no identical GNB. In samples with an
identical GNB, 8% grew less than 102 CFU/ml, 15% 102, 11%
103, 8% 104 and 5% grew 105 colony forming units (CFU)/ml.
The spectrum of isolated pre-transplant gram-negative
pathogens is displayed in Fig. 2. Nine transplant recipients
exhibited polymicrobial pre-transplant colonization, all of
which contained Pseudomonas spp. (þ methicillin-sensible
Staphylococcus aureus nZ 2, þ methicillin-resistant
S. aureus nZ 2, þ AchromobacterZ 2, þ Pandorea nZ 1,
þ Escherichia coli, þ Stenotrophomonas nZ 1).
Eighteen recipients developed BOS after a mean of 508
(114e1167) days. The likelihood of remaining BOS-free
after 1 year, 2 and 3 years was found to be 82, 78 and 63%,
respectively, in the total cohort. The onset of BOS in
patients harbouring an identical GNB was 671 (114e1054)
days vs. 362 (191e1167) days in recipients without or
transient colonization (pZ 0.63). Twenty-three out of 59
patients (34%) required at least one treatment for acute
rejection during the first 12 months. Recipients developing
BOS had 1 1 steroid pulses in the first post-operative year
vs. 0.5 0.8 in patients without BOS (pZ 0.06).Figure 2 Isolated gram-negative organisms (nZ 66).Seven patients died 480 (128e855) days after LTx. The
cause of death in three patients was sepsis, with a further
two developing respiratory failure/BOS. One died following
unrelated trauma and the remaining patient after re-do-
transplantation.
Univariate analysis demonstrated significantly lower risk
for the development of BOS in the recipients without early
or late detection of identical GNB after LTx (Table 2). BOS-
free survival was significantly better in patients without or
with transient colonization (Fig. 3). In addition to acute
rejection episodes during the first post-operative year, the
loss of colonization (early or late) proved to be a significant
covariate for BOS-free survival in multivariate Cox regres-
sion analysis (Table 3).Discussion
The present study provides further insight on the natural
course of pre-transplant colonization early and late afterGNBeairway colonization (group A, nZ 25) and CF-patients
further colonized (group B, nZ 34).
Colonization
lost (nZ 25)
Further colonized
(nZ 34)
p-Value
Daclizumab (%) 4 (16) 4 (12) 0.46
Tacrolimus (%) 6 (24) 9 (27) 0.83
Everolimus (%) 3 (12) 3 (9) 0.51
Pseudomonas
aeruginosa (%)
17 (68) 30 (88) 0.06
Burkholderia
cepacia (%)
2 (8) 3 (9) 0.65
Airway Stents (%) 3 (12) 4 (12) 0.64
Rejection
treatments
during first
post-operative
year (%)
9 (36) 14 (41) 0.45
BOS (%) 4 (16) 14 (41) 0.04
Death (%) 1 (4) 6 (18) 0.11
Figure 3 BOS-free survival of CF patients losing GNB colo-
nization (group A) and with further gram-negative colonization
(group B), pZ 0.02, log rank test.
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all CF recipients harbouring GNB pre-transplant were
colonized with an identical GNB after LTx. In identically
transplant recipients with an identical pre-transplant
pseudomonad, subsequent clearance of colonization
occurred in one-third. Eighty-two percent of these tran-
siently colonized recipients cleared GNB from the allograft
during the first 2 post-operative years, and 68% during the
first post-operative year. In this study, a link between
persistent identical gram-negative airway colonization and
BOS after lung transplantation was demonstrated. This
effect seems to be independent from other BOS risk
factors.
It was shown by our group that transplant recipients with
CF harboured different pseudomonas strains.9 Most of the
patients remained colonized with the same strain as was
cultured before lung transplantation. The frequency of re-
colonization was comparable in this study, to data from the
literature.8,9 Our genotype data support the hypothesis
that a reservoir of P. aeruginosa exists in patients withTable 3 Univariate analysis (log rank test) comparing patients d
proportional hazards model for BOS-free survival.
Covariate Univariate analysis
BOS (nZ 18) No BOS (nZ 41
Daclizumab induction (%) 4 (22) 3 (7)
Tacrolimus (%) 6 (33) 9 (22)
Everolimus (%) 0 (0) 6 (15)
Pseudomonas aeruginosa (%) 14 (78) 32 (78)
Burkholderia cepacia
complex (%)
1 (6) 4 (10)
Airway Stents (%) 2 (11) 5 (12)
Rejection treatments/1st
year (%)
11 (61) 12 (29)
Colonization lost (%) 4 (22) 21 (51)
Cut-off values used if factor was present.cystic fibrosis who undergo lung transplantation, presum-
ably located in the upper respiratory tract or trachea. The
phenomenon of transient colonization is common in the CF
population. It has been previously demonstrated that
recipients harbouring pan-resistant GNB and especially B.
cepacia14e17 have worse survival following lung trans-
plantation. This was explained by an increased number of
early post-operative infections but GNB may have addi-
tional late negative sequelae such as BOS.
Pseudomonads (e.g. P. aeruginosa, Achromobacter,
Stenotrophomonas maltophilia and B. cepacia) are oppor-
tunistic pathogens. Colonization of the lower respiratory
tract occurs only in those with impaired host defences. In
cystic fibrosis, there is a unique hostebacterial interaction
with an inflammatory response to the chronic bacterial
infection.18,19 Alginate produced by pseudomonas bacteria
leads to a characteristic biofilm within the bronchioles.
The process of phagocytosis around the biofilm leads to
liberation of proteolytic enzymes such as elastase and
oxygen radicals which gradually destroy the tissue of the
lungs in patients with cystic fibrosis. It has been shown that
colonization triggers expression of diverse cytokines by
structural airway cells, inducing neutrophil recruitment and
thereby perpetuating a cycle of airway inflammation and
destruction.20,21 Structural abnormalities seem to be more
important in the clearance of gram-negative colonies than
altered host defences. In LTx recipients aside from immu-
nosuppression, airway homeostasis is abnormal. Airway
ischemia and disruption of lymphatic vessels,22 impaired
cough reflex,23 and disturbed mucociliary clearance24 may
predispose to bacterial colonization in the pulmonary
allograft.
Loss of colonization after LTx may be due to gradual
reduction of immunosuppression but this appears unlikely
as most of our patients experienced de-colonization during
the period of maximal immunosuppression (first 2 post-
operative years). In our experience breakdown of mucosal
barriers due to post-anastomotic airway ischemia (resulting
in necrotic bronchitis) is an important obstacle, with
healing occurring usually during the first 6 post-operative
months.eveloping BOS with patients without BOS and multivariate Cox
Multivariate Cox regression model
) p-Value Adjusted
Hazard ratio
95% Confidence
interval
p-Value
0.50
0.13 0.98
0.30 0.18
0.86
0.65
0.89
0.001 8.01 2.68e24.00 <0.001
0.02 0.18 0.05e0.62 0.006
748 J. Gottlieb et al.Lower airway tract colonization may trigger neutrophil-
mediated airway inflammation. It is accepted that accu-
mulation of GNB, particularly P. aeruginosa, leads to
expression of inflammatory cytokines (interleukin-1b, -6,
and -8 and tumor necrosis factor-alfa by airway epithelial
cells). These cytokines attract neutrophils and lead to
a vicious cycle of airway inflammation and destruc-
tion.20,21,25,26 It has been recently demonstrated that
colonized BAL samples contain significantly more total
cells, along with neutrophilia and raised IL8-concentra-
tions. Patients within this group displayed a significant
reduction in FEV1 compared to matched non-colonized
BAL samples.27 Airway colonization could therefore
potentially increase airway inflammation, leading to
airway obstruction in lung transplant patients. Aside from
infection, pronounced neutrophilia is a frequent finding in
recipients displaying BOS and even precedes the onset of
BOS.28
Two recent studies have documented an association
between the pseudomonads and the development of
BOS.29,30 In our study 3-year BOS-free survival of pseudo-
monal colonized CF patients was comparable to these
studies (53% vs. 62 and 50%). In the Belgian study, 26
transplanted patients with CF colonized with different
pseudomonads (including P. aeruginosa, Acinetobacter,
Stenotrophomonas and B. cepacia) were included (total
nZ 92).30 As in our study, BOS risk was significantly
increased in the 16 colonized vs. 10 non-colonized CF
patients. In a control of 66 non-CF recipients of whom 23
were de-novo colonized BOS-free survival was not different
compared to non-colonized subjects.
In the second study, 54 out of 66 involved LTx recipients
with CF (total cohort nZ 155) had persistent colonization
with pseudomonads (cepacia and pseudomonas).29 In
contrast to our results and that from the Leuven group,
3-year BOS-free survival (nearly 80%) was significantly
better in this study in persistent colonized transplant
recipients (mainly CF patients) while it was significantly
lower in 20 de-novo colonized non-CF patients (50%).
Whether persistent pseudomonal colonization (represent-
ing spread of organisms from an upper airway reservoir)
and de-novo colonization of the allograft (may represent
a true infection of damaged airways) after LTx are both
risk factors for BOS remains elusive.
Limitations of our study include the potential risk of
contaminating respiratory samples with material from the
upper respiratory tract. Several actions were taken to try to
eliminate this confounder. These included nasal cleaning
preceding every bronchoscopy and on occasions when any
BAL fluid was considered to be contaminated according to
our criteria, it was excluded from further analysis.
Furthermore all first BAL aspirate samples were discarded
prior to quantitative culturing to ensure only material
retrieved from the alveolar compartment was analyzed.
Finally quantitative cultures were consistently used during
the study duration. Another limitation of this study was the
lack of a strict bronchoscopic surveillance protocol beyond
the first 3 post-operative months. Furthermore, in 80% of
the recipients pseudomonas species were isolated. Data on
other pseudomonads were limited. In 12 patients with non-
pseudomonas GNB, the BOS-free survival was not significant
(pZ 0.45) when comparing negative (nZ 8) and furtherpositive (nZ 4) patients following transplantation, but
number were small. De-novo colonization with non-iden-
tical pseudomonads after LTx was unlikely to influence our
results because it was rare, transient and not different
between groups.
Overall, BOS shows multifactorial predisposition with
alloimmune and non-alloimmune risk factors, with colo-
nization being only one of them. Similar prevalence of
BOS in CF patients was observed than in other diseases.31
Reflux disease and primary graft dysfunction are two
other recently recognised risk factors for BOS. Reflux is
more common in the CF population as well, while primary
graft dysfunction may be less frequent due to avoidance
of cardiopulmonary bypass and extended donors in our
CF cohort. CMV and other virus infections were not
different between the two groups as well as reflux
disease. We believe it is required to study larger patient
populations prospectively using regular, standardised
assessments in follow-up of lung transplant recipients with
CF and non-CF to answer the influence of various risk
factors for BOS.
Current data suggest it may be important to protect
lung allografts from harvesting GNB. Modification of the
perioperative management of lung transplant recipients in
this regard may be crucial. New antimicrobials against GNB
are unlikely to be available within the next years. Non-
antimicrobial strategies may therefore gain importance in
the eradication of GNB from the respiratory tract of LTx
recipients with cystic fibrosis. Sinus surgery combined
with antimicrobial lavage may reduce the risk of post-
operative infection in lung transplant recipients with cystic
fibrosis. Some transplantation groups therefore advocate
surgical drainage of the sinuses immediately before or
after transplantation.32 Topical administration of nebu-
lized antimicrobial agents via a face mask or nasal plugs
to target the sinus tract is another potential adjunctive
measure. Further potential eradication strategies
include bacterial immunization, individual tailoring to
minimize immunosuppression and topical application of
bacteriophages.
In conclusion our data demonstrate a link between
persistent pseudomonad airway colonization and BOS after
LTx. Re-Colonization with pseudomonads after LTx is
frequent but further clearance of such colonies reoccurs
later in a significant proportion of recipients with CF.
Strategies to eradicate GNB early after LTx or reduction of
bacterial load may be crucial in the future to prevent BOS.
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